Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

News

No Difference in Survival Between Minimally Invasive and Open Staging Surgeries for Patients With Non-Endometrioid Endometrial Cancer

A study found that surgical outcomes did not differ for patients whether they had minimally invasive or open primary staging surgery for non-endometrioid endometrial cancer. 

In this study, a total of 91 patients with non-endometrioid endometrial cancer were included in the analysis. Of those 91 patients, 41 underwent minimally invasive surgery and 50 underwent open surgery. The clinicopathological characteristics, survival outcomes, complications, and prognostic factors associated with progression-free survival (PFS) and overall survival (OS) were compared between the 2 surgical methods.

Between the 2 groups, there were similar rates of PFS and OS. The 5-year PFS rate was 58.7% in the minimally invasive surgery group and 58.5% in the open surgery group (P = .925). The 5-year OS rates were 73.6% and 80.3%, respectively (P = .834). Additionally, the rates of intraoperative and postoperative surgical complications were similar between the groups. For patients who underwent minimally invasive surgery, blood loss was lower and hospital stay was shorter than those who underwent open surgery. Lymphovascular space invasion was determined to be a poor prognostic factor for PFS (adjusted hazard ratio [HR], 3.054; P = .002) and OS (adjusted HR, 3.918; P = .007), and age > 60 years was a poor prognostic factor for OS alone (adjusted HR, 5.0953; P = .004).

The study authors concluded “Surgical outcomes did not differ between the minimally invasive and open surgery group in patients with non-endometrioid endometrial cancer” and “lymphovascular space invasion was a significant survival factor in this context.”


Source:

Hwong DW, Kim SI, Kim HS, et al. Comparison of survival and complications between minimally invasive and open staging surgeries in non-endometrioid endometrial cancer. Eur J Surg Oncol. 2024;50(10):108584. doi:10.1016/j.ejso.2024.108584.

Advertisement

Advertisement

Advertisement

Advertisement